At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective Evaluation of Ruxolitinib Efficacy for CNL/aCML Patients With Mutation of CSF3R
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis, Quality-of-Life Assessment, and 2 other interventions for Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative and Chronic Neutrophilic Leukemia. Completed, enrolled 51 participants across 7 sites.
Detailed Summary
This phase II trial studies how well ruxolitinib phosphate works in treating patients with chronic neutrophilic leukemia (CNL) or atypical chronic myeloid leukemia (aCML). Ruxolitinib phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for cells to reproduce. This trial also studies the genetic makeup of patients. Certain genes in cancer cells may determine how the cancer grows or spreads and how it may respond to different drugs. Studying how the genes associated with CNL and aCML respond to the study drug may help doctors learn more about CNL and aCML and improve the treatment for these diseases.
Study Details
Timeline
Interventions
Correlative studies
Ancillary studies
Ancillary studies
Given PO